---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-022617"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:42:45.274443+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Organon reports FY 2022 revenue $6.2B (-2% as-reported); Q4 GAAP EPS $0.42, provides 2023 guidance

## Summary
- FY 2022 revenue $6.174B, down 2% as-reported, up 4% ex-FX; diluted GAAP EPS $3.59, non-GAAP adjusted $5.03.
- Q4 2022 revenue $1.485B, down 7% as-reported, up 1% ex-FX; GAAP EPS $0.42, non-GAAP adjusted $0.81.
- All three franchises grew on constant-currency basis in FY 2022; Nexplanon up 11% ex-FX, Biosimilars up 17% ex-FX.
- Q4 included $36M inventory charges and $8M sales return reserve due to Heist facility market action.
- 2023 guidance: revenue $6.15B-$6.45B; Adjusted EBITDA margin 31%-33%; quarterly dividend $0.28/share declared.

## SEC filing metadata
- accession: 0001104659-23-022617
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465923022617/0001104659-23-022617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465923022617/tm234187d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-022617
- JSON: https://secwatch.observer/filing/0001104659-23-022617.json
- Plain text: https://secwatch.observer/filing/0001104659-23-022617.txt

## Key facts
- Earnings Releases
  Organon & Co. reported the fourth quarter and full year ended December 31, 2022 results: revenue $1,485 million, net income $108 million, EPS $0.42 per diluted share.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $1,485 million
  - Net income: $108 million
  - EPS: $0.42 per diluted share
  - Result: reported results
  source text: For the fourth quarter of 2022, total revenue was $1,485 million, a decrease of 7% as-reported and an increase of 1% excluding the impact of foreign currency (ex-FX), compared with the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821825/000110465923022617/0001104659-23-022617-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.